-
Mashup Score: 0Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation - 57 minute(s) ago
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care. @US_FDA #HeadandNeckCancer https://t.co/xztx1i9T9i https://t.co/eZliqQrm7g
-
-
Mashup Score: 0
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. @JSALymphomaDoc @harvardmed @ASCO #ASCO25 #Lymphoma https://t.co/LQ25B7WhLf
-
-
Mashup Score: 0
Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Beyond Treatment: How Support Groups Helped Me Embrace My New Normal #Oncology https://t.co/R9zygU2U5p
-
-
Mashup Score: 1
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025 @JSabari @lungoncdoc @MDAndersonNews @Perlmutter_CC @ASCO #ASCO25 #LungCancer https://t.co/gLqmOabxSh
-
-
Mashup Score: 0How Love Helped Me Overcome my Cancer Diagnosis - 6 hour(s) ago
Facing two life-threatening diagnoses, I overcame fear of self-injections by leaning on love, encouragement and determination to save my life.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
How Love Helped Me Overcome my Cancer Diagnosis #CancerDiagnosis https://t.co/DSDVM5qswj
-
-
Mashup Score: 2FDA Approves UGN-102 For Some With Bladder Cancer - 7 hour(s) ago
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
🚨 BREAKING: The U.S. FDA has approved UGN-102 for some patients with bladder cancer. #bladdercancer https://t.co/wSXBzCzZrF
-
-
Mashup Score: 8
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
What Patients With Genitourinary Cancers Need to Know After ASCO 2025 @JSabari @DVAraujoMD @UFHealthCancer @Perlmutter_CC @ASCO #ASCO25 https://t.co/ywbkB0oZCT
-
-
Mashup Score: 1FDA Approves Brukinsa Tablet For Various Blood Cancers - 10 hour(s) ago
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
FDA Approves Brukinsa Tablet For Various Blood Cancers @US_FDA #Oncology #MedEd #MedTwitter https://t.co/SapUo5x2Qu
-
-
Mashup Score: 4A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment - 11 hour(s) ago
Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment @MikeSerzanMD @DanaFarber @DanaFarberNews #Oncology #MedEd #KidneyCancer https://t.co/UMStcUFj1I
-
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine. @ASCO #ASCO25 #Oncology #MedEd #MedTwitter Get more insights on the news here: https://t.co/Vzwff76kAo https://t.co/t7d5fVQmLn